Form 8-K - Current report:
SEC Accession No. 0001213900-25-009213
Filing Date
2025-02-03
Accepted
2025-02-03 11:20:07
Documents
15
Period of Report
2025-02-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0229633-8k_inmed.htm   iXBRL 8-K 35097
2 NEWS RELEASE, DATED FEBRUARY 3, 2025 ea022963301ex99-1_inmed.htm EX-99.1 17553
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5102
  Complete submission text file 0001213900-25-009213.txt   239345

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20250203.xsd EX-101.SCH 3021
5 XBRL LABEL FILE inm-20250203_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inm-20250203_pre.xml EX-101.PRE 22364
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0229633-8k_inmed_htm.xml XML 3671
Mailing Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8
Business Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 25581153
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)